China SXT Pharmaceuticals-ASXTC
13F holders, Q2 2025 (June 30)4holders +2
2new positions
0sold out
$1.73avg. 13F price*
At the end of Q2 2025, 4 institutions reported holding China SXT Pharmaceuticals-A (SXTC) in their 13F filings, up 2 from Q1 2025. 2 opened new positions and 0 sold out. The largest holders were UBS Group AG ($108K), Virtu Financial LLC ($24K) and Tower Research Capital LLC (TRC) ($261).
- Company
- China SXT Pharmaceuticals-A
- CUSIP
- G2161P157
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $24K |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 71,450 shares bought, net +71,450 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| UBS Group AG | 0.00% | Add +1087.8% | 62,599 | $108K |
| Virtu Financial LLC | 0.00% | New | 13,970 | $24K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 151 | $261 |
| Acadian Asset Management LLC | 0.00% | No change | 48 | $0 |
"% of holder's portfolio" is SXTC's weight in each manager's 13F, not the share of China SXT Pharmaceuticals-A the manager owns.